Cingulate Inc. (NASDAQ:CING) Short Interest Down 95.8% in July

Cingulate Inc. (NASDAQ:CING) was the recipient of a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 8,300 shares, a drop of 95.8% from the July 15th total of 199,100 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 54,100 shares, the days-to-cover ratio is presently 0.2 days.

Cingulate Trading Up 16.6 %

Shares of CING stock opened at $2.85 on Tuesday. Cingulate has a fifty-two week low of $1.82 and a fifty-two week high of $187.20. The business’s 50 day moving average price is $0.55 and its 200-day moving average price is $0.93.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.